NRx Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From NRx Pharmaceuticals, Inc.
The firm’s live-virus COVID-19 vaccine candidate BriLife is entering a late-stage study following Phase II success, sparking hopes that its spontaneous mutations could parallel those of VOCs.
NRx’s BriLife has demonstrated strong potential in early data from a mid-stage COVID-19 trial, spurring the company on to begin a Phase IIb/III study as soon as possible.
Coronavirus Notebook: Valneva Vaccine To Begin EU Rolling Review, Synairgen Reports Progress With Inhaled IFN-Beta
The European Parliament is pushing for more of a say in how Europe’s new emergency response authority, HERA, deals with R&D and procurement of vaccines and therapies in times of health crises. NRx Therapeutics says it will continue to seek US approval of aviptadil for COVID-19.
The US FDA has rejected an emergency use authorization application for NRx Pharmaceuticals’ Zyesami (aviptadil) for use in COVID-19 patients with respiratory failure. The UK has revamped its emergency delivery service for drugs that experience shortages as a result of the pandemic and other factors.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- NeuroRx, Inc.